Charles M. Perou
Affiliations: | Bioinformatics & Computational Biology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Bioinformatics, Genetics, OncologyGoogle:
"Charles Perou"Children
Sign in to add trainee| Katherine A. Hoadley | grad student | 2006 | UNC Chapel Hill |
| Daniel S. Oh | grad student | 2006 | UNC Chapel Hill |
| Jason I. Herschkowitz | grad student | 2008 | UNC Chapel Hill |
| Joel S. Parker | grad student | 2010 | UNC Chapel Hill |
| Aaron R. Thorner | grad student | 2010 | UNC Chapel Hill |
| Hann-Hsiang Chao | grad student | 2012 | UNC Chapel Hill |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Han YJ, Liu S, Hardeman A, et al. (2024) The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Yazdimamaghani M, Kolupaev OV, Lim C, et al. (2024) Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy. Biorxiv : the Preprint Server For Biology |
| Fernandez-Martinez A, Rediti M, Tang G, et al. (2024) Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. Jama Oncology |
| Hamilton AM, Walens A, Van Alsten SC, et al. (2024) BIRC5 expression by race, age and clinical factors in breast cancer patients. Breast Cancer Research : Bcr. 26: 50 |
| Pascual T, Fernandez-Martinez A, Agrawal Y, et al. (2024) Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. Npj Breast Cancer. 10: 20 |
| Conte B, Brasó-Maristany F, Hernández AR, et al. (2024) A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. Ebiomedicine. 102: 105043 |
| Jiang YZ, Ma D, Jin X, et al. (2024) Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nature Cancer |
| Ma CX, Suman VJ, Sanati S, et al. (2024) Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. Jama Oncology |
| Zagami P, Fernandez-Martinez A, Rashid NU, et al. (2023) Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. Jama Network Open. 6: e2348814 |
| Xiang S, Zhang W, Liu S, et al. (2023) PAIRWISE NONLINEAR DEPENDENCE ANALYSIS OF GENOMIC DATA. The Annals of Applied Statistics. 17: 2924-2943 |